➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Johnson and Johnson
Baxter
Mallinckrodt
AstraZeneca

Last Updated: September 22, 2020

DrugPatentWatch Database Preview

Patent: 8,541,203

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,541,203
Title:Activatable binding polypeptides and methods of identification and use thereof
Abstract: Activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM) are provided. Activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM are provided. Furthermore, ABPs which contain a first TBM, a second TBM and a CM are provided. The ABPs exhibit an \"activatable\" conformation such that at least one of the TBMs is less accessible to target when uncleaved than after cleavage of the CM in the presence of a cleaving agent capable of cleaving the CM. Further provided are libraries of candidate ABPs, methods of screening to identify such ABPs, and methods of use. Further provided are ABPs having TBMs that bind VEGF, CTLA-4, or VCAM, ABPs having a first TBM that binds VEGF and a second TBM that binds FGF, as well as compositions and methods of use.
Inventor(s): Daugherty; Patrick Sean (Santa Barbara, CA), Stagliano; Nancy (Santa Barbara, CA), Thomas; Jerry (Goleta, CA), West; James W. (Santa Barbara, CA), Sagert; Jason (Santa Barbara, CA)
Assignee: The Regents of the University of California (Oakland, CA) CytomX Therapeutics, Inc. (South San Francisco, CA)
Application Number:13/411,416
Patent Claims:see list of patent claims

Details for Patent 8,541,203

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial The Regents of the University of California (Oakland, CA) CytomX Therapeutics, Inc. (South San Francisco, CA) 2027-08-22 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial The Regents of the University of California (Oakland, CA) CytomX Therapeutics, Inc. (South San Francisco, CA) 2027-08-22 RX Orphan search
Genentech LUCENTIS ranibizumab INJECTABLE; INJECTION 125156 001 2006-06-30   Start Trial The Regents of the University of California (Oakland, CA) CytomX Therapeutics, Inc. (South San Francisco, CA) 2027-08-22 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Express Scripts
McKesson
Merck
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.